Some US FDA Decisions May Have Been Different If Technology Had Been Upgraded, Woodcock Says
Principal Deputy Commissioner Woodcock is overseeing an enterprise-wide technology campaign intended to improve access to agency information and data.
You may also be interested in...
US FDA Neurology Drugs Program Gains Boost In FY 2023 Funding Bill Amid Calls To Clarify Development Policies
US FDA gains a nearly 7% increase in non-user fee funding, some of which will go for neurology drug guidance.
FDA Commissioner Robert Califf says mentioning China helps increase congressional support.
Janet Woodcock’s imminent departure from FDA has been predicted often during her tenure. Her latest project may keep her there longer than even she thought possible.